Hydrocortisone Acetate Suppositories, 25 Mg

Hydrocortisone acetate suppositories are indicated for use in inflamed hemorrhoids, post-irradiation (factitial) proctitis, as an adjunct in the treatment of chronic ulcerative colitis, cryptitis, other inflammatory conditions of anorectum, and pruritus ani.

Usual dosage: One suppository in the rectum twice daily morning and night for two weeks, in nonspecific proctitis. In more severe cases, one suppository three times daily; or two suppositories twice daily. In factitial proctitis, recommended therapy is six to eight weeks or less, according to response.

Hydrocortisone acetate suppositories are contraindicated in those patients having a history of hypersensitivity to hydrocortisone acetate or any of the components.

The following local adverse reactions have been reported with hydrocortisone acetate suppositories; burning, itching, irritation, dryness, folliculitis, hypopigmentation, allergic contact dermatitis, secondary infection.



To report SUSPECTED ADVERSE REACTIONS, contact Rising Pharma Holdings, Inc. at 1-844-874-7464, or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

Hydrocortisone acetate suppositories 25 mg are off-white, smooth surfaced and bullet shaped with one pointed end.

Box of 12 suppositories, NDC 16571-676-21

Box of 24 suppositories, NDC 16571-676-42

Hydrocortisone acetate suppositories 30 mg are off-white, smooth surfaced and bullet shaped with one pointed end.

Box of 12 suppositories, NDC 16571-164-21

Each Hydrocortisone Acetate Suppository for rectal administration contains 25 mg hydrocortisone acetate, USP in a specially blended hydrogenated vegetable oil base.

Each Hydrocortisone Acetate Suppository for rectal administration contains 30 mg hydrocortisone acetate, USP in a specially blended hydrogenated vegetable oil base.

Hydrocortisone acetate is a corticosteroid. The molecular weight of hydrocortisone acetate is 404.50.

Chemically, hydrocortisone acetate is pregn-4-ene-3, 20 dione, 21-(acetyloxy)-11, 17-dihydroxy-, (11ß)- with an empirical formula of C H O and the following structural formula:

Store at 20°-25°C (68°-77°F) [See USP Controlled Room Temperature]. Excursions permitted to 15°-30°C (59°-86°F). Store away from heat. Protect from freezing. Avoid contact

with eyes.



KEEP THIS AND ALL DRUGS OUT OF THE REACH OF CHILDREN. In case of accidental ingestion, seek professional assistance or contact a Poison Control Center immediately.

PHARMACIST

This product is not an Orange Book rated product, therefore all prescriptions using this product shall be subject to state and federal statutes as applicable. This product has not been subjected to FDA therapeutic or other equivalency testing. There are no claims of bioequivalence or therapeutic equivalence. Each person recommending a prescription substitution using this product shall make such recommendation based on his/her professional knowledge and opinion, upon evaluating the active ingredients, inactive ingredients, excipients and chemical information contained within the enclosed prescribing information.



Rx Only



Distributed by:

Rising Pharma Holdings, Inc.

East Brunswick, NJ 08816



Manufactured by:

Quagen Pharmaceuticals LLC

West Caldwell, NJ 07006



52030/52050

Revised: 02/2024

If signs and symptoms of systemic overdosage occur, discontinue use.

Do not use hydrocortisone acetate suppositories unless adequate proctologic examination is made.



If irritation develops, the product should be discontinued and appropriate therapy instituted.



In the presence of an infection, the use of an appropriate antifungal or antibacterial agent should be instituted. If a favorable response does not occur promptly, hydrocortisone acetate should be discontinued until the infection has been adequately controlled.

Carcinogenesis

No long-term studies in animals have been performed to evaluate the carcinogenic potential of corticosteroid suppositories.

In laboratory animals, topical steroids have been associated with an increase in the incidence of fetal abnormalities when gestating females have been exposed to rather low dosage levels. There are no adequate and well-controlled studies in pregnant women.



Hydrocortisone acetate suppositories should only be used during pregnancy if the potential benefit justifies the risk of the fetus. Drugs of this class should not be used extensively on pregnant patients, in large amounts, or for prolonged periods of time.



It is not known whether this drug is excreted in human milk, and because many drugs are excreted in human milk and because of the potential for serious adverse reactions in nursing infants from hydrocortisone acetate suppositories, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother.

In normal subjects, about 26% of hydrocortisone acetate is absorbed when the hydrocortisone acetate suppository is applied to the rectum. Absorption of hydrocortisone acetate may vary across abraded or inflamed surfaces.

Topical steroids are primarily effective because of their anti-inflammatory, anti-pruritic and vasoconstrictive action.

Drug abuse and dependence have not been reported in patients treated with hydrocortisone acetate suppositories.

Rising^®                                 NDC 16571-676-21

Hydrocortisone Acetate Suppositories

25 mg



For Rectal Administration



12 Adult Suppositories        Rx only

Rising ^®                                  NDC 16571-164-21

Hydrocortisone Acetate Suppositories

30 mg



For Rectal Administration



12 Adult Suppositories        Rx only

Store at 20°-25°C (68°-77°F) [See USP Controlled Room Temperature]. Excursions permitted to 15°-30°C (59°-86°F). Store away from heat. Protect from freezing. Avoid contact

with eyes.



KEEP THIS AND ALL DRUGS OUT OF THE REACH OF CHILDREN. In case of accidental ingestion, seek professional assistance or contact a Poison Control Center immediately.

PHARMACIST

This product is not an Orange Book rated product, therefore all prescriptions using this product shall be subject to state and federal statutes as applicable. This product has not been subjected to FDA therapeutic or other equivalency testing. There are no claims of bioequivalence or therapeutic equivalence. Each person recommending a prescription substitution using this product shall make such recommendation based on his/her professional knowledge and opinion, upon evaluating the active ingredients, inactive ingredients, excipients and chemical information contained within the enclosed prescribing information.



Rx Only



Distributed by:

Rising Pharma Holdings, Inc.

East Brunswick, NJ 08816



Manufactured by:

Quagen Pharmaceuticals LLC

West Caldwell, NJ 07006



52030/52050

Revised: 02/2024

If signs and symptoms of systemic overdosage occur, discontinue use.

Each Hydrocortisone Acetate Suppository for rectal administration contains 25 mg hydrocortisone acetate, USP in a specially blended hydrogenated vegetable oil base.

Each Hydrocortisone Acetate Suppository for rectal administration contains 30 mg hydrocortisone acetate, USP in a specially blended hydrogenated vegetable oil base.

Hydrocortisone acetate is a corticosteroid. The molecular weight of hydrocortisone acetate is 404.50.

Chemically, hydrocortisone acetate is pregn-4-ene-3, 20 dione, 21-(acetyloxy)-11, 17-dihydroxy-, (11ß)- with an empirical formula of C H O and the following structural formula:

Do not use hydrocortisone acetate suppositories unless adequate proctologic examination is made.



If irritation develops, the product should be discontinued and appropriate therapy instituted.



In the presence of an infection, the use of an appropriate antifungal or antibacterial agent should be instituted. If a favorable response does not occur promptly, hydrocortisone acetate should be discontinued until the infection has been adequately controlled.

Carcinogenesis

No long-term studies in animals have been performed to evaluate the carcinogenic potential of corticosteroid suppositories.

Hydrocortisone acetate suppositories 25 mg are off-white, smooth surfaced and bullet shaped with one pointed end.

Box of 12 suppositories, NDC 16571-676-21

Box of 24 suppositories, NDC 16571-676-42

Hydrocortisone acetate suppositories 30 mg are off-white, smooth surfaced and bullet shaped with one pointed end.

Box of 12 suppositories, NDC 16571-164-21

The following local adverse reactions have been reported with hydrocortisone acetate suppositories; burning, itching, irritation, dryness, folliculitis, hypopigmentation, allergic contact dermatitis, secondary infection.



To report SUSPECTED ADVERSE REACTIONS, contact Rising Pharma Holdings, Inc. at 1-844-874-7464, or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

Hydrocortisone acetate suppositories are contraindicated in those patients having a history of hypersensitivity to hydrocortisone acetate or any of the components.

In laboratory animals, topical steroids have been associated with an increase in the incidence of fetal abnormalities when gestating females have been exposed to rather low dosage levels. There are no adequate and well-controlled studies in pregnant women.



Hydrocortisone acetate suppositories should only be used during pregnancy if the potential benefit justifies the risk of the fetus. Drugs of this class should not be used extensively on pregnant patients, in large amounts, or for prolonged periods of time.



It is not known whether this drug is excreted in human milk, and because many drugs are excreted in human milk and because of the potential for serious adverse reactions in nursing infants from hydrocortisone acetate suppositories, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother.

In normal subjects, about 26% of hydrocortisone acetate is absorbed when the hydrocortisone acetate suppository is applied to the rectum. Absorption of hydrocortisone acetate may vary across abraded or inflamed surfaces.

Topical steroids are primarily effective because of their anti-inflammatory, anti-pruritic and vasoconstrictive action.

Hydrocortisone acetate suppositories are indicated for use in inflamed hemorrhoids, post-irradiation (factitial) proctitis, as an adjunct in the treatment of chronic ulcerative colitis, cryptitis, other inflammatory conditions of anorectum, and pruritus ani.

Usual dosage: One suppository in the rectum twice daily morning and night for two weeks, in nonspecific proctitis. In more severe cases, one suppository three times daily; or two suppositories twice daily. In factitial proctitis, recommended therapy is six to eight weeks or less, according to response.

Drug abuse and dependence have not been reported in patients treated with hydrocortisone acetate suppositories.

Rising^®                                 NDC 16571-676-21

Hydrocortisone Acetate Suppositories

25 mg



For Rectal Administration



12 Adult Suppositories        Rx only

Rising ^®                                  NDC 16571-164-21

Hydrocortisone Acetate Suppositories

30 mg



For Rectal Administration



12 Adult Suppositories        Rx only